Elimination of Tumor Suppressor Proteins during Liver Carcinogenesis
DOI:
https://doi.org/10.17140/CSMMOJ-1-104Keywords:
Liver cancer, Tumor suppressor genes, Gankyrin, C/EBPΑ, Rb, p53, HNF4αAbstract
Liver cancer is one of the most lethal cancers. Quiescent liver expresses up to 20 tumor suppressor proteins including Rb, p53, CCAAT-Enhancer-Binding Protein (C/EBP)α, Hepatocyte Nuclear Factor (HNF4)α and p16 and it is well protected from development of liver cancer. However, the negative control of liver proliferation by these factors and other tumor suppressor genes is eliminated in liver cancer. Studies of liver regeneration after surgery and injury have provided fundamental mechanisms on how liver neutralizes tumor suppressor proteins for the time of regeneration; however, studies of liver cancer in animal models and in human samples showed several additional pathways of this neutralization. One of these additional pathways includes activation of a small subunit of the proteasome, Gankyrin. Gankyrin is dramatically increased in human hepatocellular carcinoma (HCC) and in animal models of carcinogenesis. Once activated Gankyrin triggers degradation of main tumor suppressor proteins during development of liver cancer using slightly different mechanisms. Recent studies identified mechanisms which repress Gankyrin in quiescent livers and mechanisms of activation of Gankyrin in liver cancer. These mechanisms involve a communication between Farnesoid X Receptor (FXR) signaling and chromatin remodelling proteins mediated by members of C/EBP family. It has been recently shown that C/EBPα plays a critical role in this network and that the activation of C/EBPα in cirrhotic livers with HCC inhibits cancer progression. This C/EBPα- dependent inhibition of liver cancer involves activation of a majority of tumor suppressor genes and repression of tumor initiating pathways such as β-catenin and c-myc. These recent findings provide a background for FXR-based and C/EBPα-based approaches to treat liver cancer.
References
Fausto N, Campbell JS, Riehle KJ. Liver regeneration. J He-patol. 2012; 57: 692-694. doi: 10.1002/jcp.21172
Jones K, Timchenko L, Timchenko NA. The role of CUGBP1 in age-dependent changes of liver functions. Ageing Research Reviews. 2012; 11: 442-449. doi: 10.1016/j.arr.2012.02.007
Riehle KJ, Dan YY, Campbell JS, Fausto N. New concepts in liver regeneration. J Gastroenterol Hepato.l 2011; 26 Suppl 1: 203-212. doi: 10.1111/j.1440-1746.2010.06539.x
Timchenko NA. Aging and liver regeneration. Trends Endocrinol Metab. 2009; 20: 171-176. doi: 10.1016/j. tem.2009.01.005
Michalopoulos G. Principles of liver regeneration and Growth Homeostasis. Comprehensive Physiology. 2013; 3: 485-513. doi: 10.1002/cphy.c120014
Michalopoulos G. Advances in liver regeneration. Expert Re-view of Gastroenterology. & Hepatology. 2014; 26: 1-11. doi: 10.1586/17474124.2014.934358
Nygard IE, Mortensen KE, Hedegaard J, et al. The genetic regulation of the terminating phase of liver regeneration. Comp Hepatol. 2012; 11: 3. doi: 10.1186/1476-5926-11-3
Rychtrmoc D, Hubalkova L, Viskova A, Libra A, Buncek M, Cervinkova Z. Transcriptome temporal and functional analysis of liver regeneration termination. Physiol Res. 2012; 61 Suppl 2: S77-S92.
Chen H, Sun Y, Dong R, et al. Mir-34a is upregulated during liver regeneration in rats and is associated with the suppression of hepatocyte proliferation. PLoS One. 2011; 6: e20238. doi:
1371/journal.pone.0020238 10. Yuan B, Dong R, Shi D, et al. Down-regulation of miR-23b may contribute to activation of the TGF-beta1/Smad3 signalling pathway during the termination stage of liver regeneration. FEBS Lett. 2011; 585: 927-934. doi: 10.1016/j.febslet.2011.02.031
Apte U, Gkretsi V, Bowen WC, et al. Enhanced liver regener-ation following changes induced by hepatocyte-specific genetic ablation of integrin-linked kinase. Hepatology. 2009; 50: 844- 851. doi: 10.1002/hep.23059
Koral K, Paranjpe S, Bowen WC, Mars W, Luo J, Mich-alopoulos GK. Leukocyte specific protein-1: A novel regulator of hepatocellular proliferation and migration deleted in human HCC. Hepatology. 2014. doi: 10.1002/hep.27444
Jin J, Hong IH, Lewis K, et al. Cooperation of C/EBP family proteins and chromatin remodeling proteins is essential for ter-mination of liver regeneration in mice. Hepatology. 2014. doi: 10.1002/hep.27295
Jin J, Wang GL, Iakova P, et al. Epigenetic changes play critical role in age-associated dysfunctions of the liver. Aging Cell. 2010; 9: 895-910. doi: 10.1111/j.1474-9726- .2010.00617.x
Wang GL, Shi X, Haefliger S, et al. Elimination of C/EBPal-pha through the ubiquitin-proteasome system promotes the development of liver cancer in mice. J Clin Invest. 2010; 120: 2549-2562. doi: 10.1172/JCI41933
Hong IH, Lewis K, Iakova P, et al. Age-associated Change of C/EBP Family Proteins Causes Severe Liver Injury and Ac-celeration of Liver Proliferation after CCl4 Treatments. J Biol Chem. 2014; 289: 1106-1118. doi: 10.1074/jbc.M113.526780
Jin J, Iakova P, Breaux M, et al. Increased expression of en-zymes of triglyceride synthesis is essential for the development of hepatic steatosis. Cell Rep. 2013; 3: 831-843. doi: 10.1016/j. celrep.2013.02.009
Jin J, Iakova P, Jiang Y, et al. Transcriptional and transla-tional regulation of C/EBPbeta-HDAC1 protein complexes con-trols different levels of p53, SIRT1, and PGC1alpha proteins at the early and late stages of liver cancer. J Biol Chem. 2013; 288: 14451-14462. doi: 10.1074/jbc.M113.460840
Michalopoulos G. Terminating hepatocyte proliferation dur-ing liver regeneration: The roles of two members of the same family (C/EBP α and β) with opposing actions. Hepatology. 2014. doi: 10.1002/hep.27329
Zhao B, Wei X, Li W, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007; 21(21): 2747-2761. doi: 10.1101/gad.1602907
Wang C, Zhang L, He Q, et al. Differences in Yes-associated protein and mRNA levels in regenerating liver and hepatocellu-lar carcinoma. Mol Med Rep. 2012; 5(2): 410-414. doi: 10.3892/ mmr.2011.640
Grijalva JL, Huizenga M, Mueller K, et al. Dynamic altera-tions in Hippo signaling pathway and YAP activation during liv-er regeneration. Am J Physiol Gastrointest Liver Physiol. 2014; 307(2): G196-G204. doi: 10.1152/ajpgi.00077.2014
Yimlamai D, Christodoulou C, Galli GG, et al. Hippo path-way activity influences liver cell fate. Cell. 2014; 157(6): 1324- 1338. doi: 10.1016/j.cell.2014.03.060
Martin J, Dufour JF. Tumor suppressor and hepatocellular carcinoma. World J Gastroenterol. 2008; 14(11): 1720-1733. doi: 10.3748/wjg.14.1720
Callegari E, Gramantieri L, Domenicali M, D’Abundo L, Sabbioni S, Negrini M. MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. Cell Death Differ. 2014. doi: 10.1038/cdd.2014.136
Yin H, Peng X, Ren P, Cheng B, Li S, Qin C. MicroRNAs as a novel class of diagnostic biomarkers in detection of hepa-tocellular carcinoma: a meta-analysis. Tumour Biol. 2014. doi: 10.1007/s13277-014-2544-2
Khare S, Zhang Q, Ibdah JA. Epigenetics of hepatocellu-lar carcinoma: role of microRNA. World J Gastroenterol. 2013; 19(33): 5439-5445. doi: 10.3748/wjg.v19.i33.5439
Revill K, Wang T, LachenmayerA, et al. Genome-wide methy-lation analysis and epigenetic unmasking identify tumor suppres-sor genes in hepatocellular carcinoma. Gastroenterology. 2013; 145(6): 1424-35.e1-25. doi: 10.1053/j.gastro.2013.08.055
Xue W, Kitzing T, Roessler S, et al. SWA cluster of cooper-ating tumor-suppressor gene candidates in chromosomal dele-tions. Proc Natl Acad Sci U S A. 2012; 109(21): 8212-8217. doi: 10.1073/pnas.1206062109
Aguirre E, Renner O, Narlik-Grassow M, Blanco-Aparicio C. Genetic Modeling of PIM Proteins in Cancer: Proviral Tagging and Cooperation with Oncogenes, Tumor Suppressor Genes, and Carcinogens. Front Oncol. 2014; 4: 109. doi: 10.3389/ fonc.2014.00109. eCollection 2014
Wolosz D, Walczak A, Wilczynski GM, Szparecki G, Wil-czek E, Gornicka B. Deleted in liver cancer 1 expression and localization in hepatocellular carcinoma tissue sections. Oncol Lett. 2014; 8(2): 785-788. doi: 10.3892/ol.2014.2216
Zimonjic DB, Popescu NC. Role of DLC1 tumor suppres-sor gene and MYC oncogene in pathogenesis of human hepa-tocellular carcinoma: potential prospects for combined targeted therapeutics. Int J Oncol. 2012; 41(2): 393-406. doi: 10.3892/ ijo.2012.1474
Zhou X, Thorgeirsson SS, Popescu NC. Restoration of DCL-1 gene expression induces apoptosisand inhibits both cell growth and tumorigenecity in human hepatocarcinima cells. On-cogene. 2014; 23: 1308-1313. doi: 10.1038/sj.onc.1207246
Zhao H, Wang J, Han Y, et al. ARID2: a new tumorsuppres-sor gene in hepatocellular carcinoma. Oncotarget. 2011; 2(11): 886-891.
Baltayiannis G, Baktayiannis N, Tsianov EV. Suppressors of cytokine signaling as tumor suppressors. Silencing of SOC3 facilitates tumor formation and growth in lung and liver. J Boun. 2008; 13: 263-265.
Vousden KH, Prives C. Blinded by light: the growing complexity of p53. Cell. 2009; 137: 413-431. doi: 10.1016/j. cell.2009.04.037
Kurinna S, Stratton SA, Coban Z, et al. p53 regulates a mi-totic transcription program and determines ploidy in normal mouse liver. Hepatology. 2013; 57(5): 2004-2013. doi: 10.1002/ hep.26233
Kirstein MM, Vogel A. The pathogenesis of hepato-cellular carcinoma. Dig Dis. 2014; 32(5): 545-553. doi: 10.1159/000360499
Hernandez-Boussard T, Rodrigez-Tome P, Montesano R, Hainaout P. IARC p53 mutation database: a rational data-base to compile and analyze p53 mutations in human tumors and cell lines. International Agency fo Research on Cancer. Human Mutat. 1999; 14: 1-8. doi: 10.1002/(SICI)1098-1004- (1999)14:1<1::AID-HUMU1>3.0.CO;2-H
Vaughan C, Pearsall I, Yeudall A, Deb SP, Deb S. p53: Its Mutations and Their Impact on Transcription. Subcell Biochem. 2014; 85: 71-90. doi: 10.1007/978-94-017-9211-0_4
Pant V, Lozano G. Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev. 2014; 28(16): 1739- 1751. doi: 10.1101/gad.247452.114
Rodriguez MS, Desterro JM, Lain S, Lane DP, Hay RT. Mul-tiple C-terminal lysine residues target p53 for ubiquitin-protea-some-mediated degradation. Mol Cell Biol. 2000; 20(22): 8458- 8467. doi: 10.1128/MCB.20.22.8458-8467.2000
Lukashchuk N, Vousden KH. Ubiquitination and degrada-tion of mutant p53. Mol Cell Biol. 2007; 27: 8284-8295. doi: 10.1128/MCB.00050-07
Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J. 1993; 12(2): 461- 468. doi: 10.1101/gad.1941710
Wu X, Bayle JH, Olson D, LevineAJ. The p53-mdm-2 auto regulatory feedback loop. Gen & Dev. 1993; 7: 1126-1132.
Saucedo LG, Carsten BP, Seavey SE, Albee LD Perry ME. Regulation of transcriptional activity of p53 gene by p53 in re-sponse to UV radiation. Cell Growth Differ. 1998; 9: 119-130.
Pand V, Lozano G. Dissecting the p53-mdm2 feedback loop in vivo: uncoupling the role of p53 stability and activity. Onco-target. 2014; 5: 1149-1156.
Conner EA, Lemmer ER, Omori M, Wirth PJ, Factor VM, Thorgeirsson SS. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis. Oncogene. 2000 19(44): 5054- 5062.
Zhan L, Huang C, Meng XM, et al. Promising roles of mam-malian E2Fs in hepatocellular carcinoma. Cell Signal. 2014; 26(5): 1075-1081. doi: 10.1016/j.cellsig.2014.01.008
Ghazaryan S, Sy C, Hu T, et al. Inactivation of Rb and E2f8 synergizes to trigger stressed DNA replication during erythroid terminal differentiation. Mol Cell Biol. 2014; 15: 2833-2847. doi: 10.1128/MCB.01651-13
Pandit SK, Westendorp B, Nantasanti S, et al. E2F8 is es-sential for polyploidization in mammalian cells. Nat Cell Biol. 2012; 11: 1181-1191. doi: 10.1038/ncb2585
Delgado I, Fresnedo O, Iglesias A, et al. A role for transcrip-tion factor E2F2 in hepatocyte proliferation and timely liver regeneration. Am J Physiol Gastrointest Liver Physiol. 2011; 301(1): G20-G31. doi: 10.1152/ajpgi.00481.2010
Iakova P, Awad SS, and Timchenko NA. Aging reduces proliferative capacities of liver by switching pathways of C/ EBP growth arrest. Cell. 2003; 113: 495-506. doi: http://dx.doi. org/10.1016/S0092-8674(03)00318-0
Timchenko NA. Old livers: C/EBP meets new partners. Cell Cycle. 2003; 2: 445-446. doi: 10.4161/cc.2.5.467
Timchenko NA, Wilde M, Darlington GJ. C/EBP regulates formation of S-phase specific E2F/p107 complexes in livers of newborn mice. Mol Cell Biol. 1999; 19:2936-2945.
Rickheim DG, Nelsen CJ, Fassett JT, Timchenko NA, Han-sen LK, Albrecht JH. Differential regulation of cyclins D1 and D3 in hepatocyte proliferation. Hepatology. 2002; 36(1): 30-38. doi: 10.1053/jhep.2002.33996
Lee K, Lee KM, Kim TJ, et al. The nuclear 16-kD protein methylation increases in the early period of liver regeneration in a hepatectomized rat. Exp Mol Med. 2004; 36(6): 563-571. doi: 10.1038/emm.2004.72
Wang MJ, Chen F, Li JX, et al. Reversal of hepatocyte se-nescence after continuous in vivo cell proliferation. Hepatology. 2014; 60(1): 349-361. doi: 10.1002/hep.27094
Zhu C, Ikemoto T, Utsunomiya T, et al. Senescence-related genes possibly responsible for poor liver regeneration after he-patectomy in elderly patients. J Gastroenterol Hepatol. 2014; 29(5): 1102-1108. doi: 10.1111/jgh.12468
Hui AM, Makuuchi M, Li X, Cell cycle regulators and hu-man hepatocarcinogenesis. Hepatogastroenterology. 1988; 45: 1635-1642.
Pulling LC, Klinge DM, Belinsky SA. p16INK4a and β-catenin alterations in rat liver tumors induced by NNK.Carcino-genesis. 2001; 22(3): 461-466. doi: 10.1093/carcin/22.3.461
Nishida N, Kudo M. Recent advancements in comprehensive genetic analyses for human hepatocellular carcinoma. Oncology. 2013; 84 Suppl 1: 93-97. doi: 10.1159/000345897
Nishida N, Goel A. Genetic and epigenetic signatures in hu-man hepatocellular carcinoma: a systematic review. Curr Genom-ics. 2011; 12(2): 130-137. doi: 10.2174/138920211795564359
Dominguez-Malagón H, Gaytan-Graham S. Hepatocellular carcinoma: an update. Ultrastruct Pathol. 2001; 25(6): 497- 516.
Azechi H, Nishida N, Fukuda Y, et al. Disruption of the p16/ cyclin D1/retinoblastoma protein pathway in the majority of human hepatocellular carcinomas. Oncology. 2001; 60(4): 346- 354. doi: 10.1159/000058531
Viatour P, Ehmer U, Saddic LA, et al. Notch signaling in-hibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med. 2011; 208(10): 1963-1976. doi: 10.1084/ jem.20110198
Ehmer U, Zmoos AF, Auerbach RK, et al. Organ size con-trol is dominant over Rb family inactivation to restrict prolif-eration in vivo. Cell Rep. 2014; 8(2): 371-381. doi: 10.1016/j. celrep.2014.06.025
Johnson PE. Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors. J Cell Science. 2005; 118: 2545-2455.
Timchenko NA, Harris TE, Wilde M, et al. CCAAT/enhanc-er binding protein alpha regulates p21 protein and hepatocyte proliferation in newborn mice. Mol Cell Biol. 1997; 17: 7353- 7361.
Flodby PC, Barlow H., Kalefjord L, Ahrlund-Richer L, Xanthopolous KG. Increased hepatic cell proliferation and lung abnormalities in mice deficient in CCAAT/Enhancer binding protein α. J Biol Chem. 1996; 271: 24753-24760. doi: 10.1074/ jbc.271.40.24753
Soriano HE, Kang DC, Finegold M, et al. Lack of C/EBPα gene expression results in increased DNA synthesis and in an in-creased frequency of immortalization of freshly isolated mouse hepatocytes. Hepatology. 1998; 27: 392-401.
Wang H, Goode T, Iakova P, Albrecht J, Timchenko NA. C/ EBPα triggers proteasome-dependent degradation of cdk4 dur-ing growth arrest. EMBO J. 2002; 21: 930-941. doi: 10.1093/ emboj/21.5.930
Wang H, Iakova P, Wilde M, et al. C/EBPα arrests cell pro-liferation through direct inhibition of cdk2 and cdk4. Molecular Cell. 2001; 8: 817-828. doi: http://dx.doi.org/10.1016/S1097- 2765(01)00366-5
Tan EH, Hooi SC, Laban M, et al. CCAAT/Enhancer Bind-ing Protein Knock-in Mice Exhibit Early Liver Glycogene Stor-age and Reduced Susceptibility to Hepatocellular Carcinoma. Cancer Res. 2005; 65: 10330-10337. doi: 10.1158/0008-5472. CAN-04-4486
Wang G-L, Iakova P, Wilde M, Awad S, Timchenko NA. Liver tumors escape negative control of proliferation via PI3K/ Akt-mediated block of C/EBPα growth inhibitory activity. Gen & Dev. 2004: 18:912-925. doi: 10.1101/gad.1183304
Wang G-L, Shi X, Salisbury E, et al. Cyclin D3 maintains growth-inhibitory activity of C/EBPα by stabilizing C/EBPα-cdk2 and C/EBPα-Brm complexes. Mol Cell Biol. 2006; 26: 2570-2582. doi: 10.1128/MCB.26.7.2570-2582.2006
Wang G-L, Shi X, Salisbury E, Timchenko NA. Regulation of apoptotic and growth inhibitory activities of C/EBPα in dif-ferent cell lines. Exp Cell Research. 2008; 314: 1626-1639. doi: 10.1016/j.yexcr.2008.01.028
Reebye V, Sætrom P, Mintz PJ, et al. Novel RNA oligonu-cleotide improves liver function and inhibits liver carcinogen-esis in vivo. Hepatology. 2014; 59(1): 216-227. doi: 10.1002/ hep.26669
Tomizawa M, Watanabe K, Saicho H, Nakagawara A, Taga-wa M. Down-regulated expression of the CCAAT/enhancer binding protein alpha and beta in human hepatocellular carci-noma: a possible prognostic marker. Anticancer Res. 2003; 23: 351-354.
Tseng HH, Hwang YH, Yeh KT, Chang JG, Chen YL, Yu HS. Reduced expression of C/EBPα protein in hepatocellular carci-noma is associated with advanced tumor stage and shortened patient survival. J Cancer Res Clin Oncol. 2009; 135: 241-247. doi: 10.1007/s00432-008-0448-5
Babeu JP, Boudreau F. Hepatocyte nuclear factor 4-alpha in-volvement in liver and intestinal inflammatory networks. World J Gastroenterol. 2014; 20(1): 22-30. doi: 10.3748/wjg.v20.i1.22
Parviz F, Matullo C, Garrison WD, et al. Hepatocyte nuclear factor 4alpha controls the development of a hepatic epithelium and liver morphogenesis. Nat Genet. 2003; 34(3): 292-296. doi: 10.1038/ng1175
Lemaigre F, Zaret KS. Liver development update: new embryo models, cell lineage control, and morphogenesis. Curr Opin Genet Dev. 2004; 14(5): 582-950. doi: 10.1016/j. gde.2004.08.004
Chellappa K, Jankova L, Schnabl JM, et al. Src tyrosine ki-nase phosphorylation of nuclear receptor HNF4α correlates with isoform-specific loss of HNF4α in human colon cancer. Proc Natl Acad Sci U S A. 2012; 109(7): 2302-2307. doi: 10.1073/ pnas.1106799109
Yao D, Peng S, Dai C. The role of hepatocyte nuclear fac-tor 4alpha in metastatic tumor formation of hepatocellular carcinoma and its close relationship with the mesenchymal-epithelial transition markers. BMC Cancer. 2013; 13: 432. doi: 10.1186/1471-2407-13-432
Zhang B, Wang J, Wang X, et al. Proteogenomic characteriza-tion of human colon and rectal cancer. Nature. 2014; 513(7518): 382-387. doi: 10.1038/nature13438
Bonzo JA, Ferry CH, Matsubara T, Kim JH, Gonzalez FJ. Suppression of hepatocyte proliferation by hepatocyte nuclear factor 4α in adult mice. J Biol Chem. 2012; 287(10): 7345-7356. doi: 10.1074/jbc.M111.334599
Hatziapostolou M, Polytarchou C, Aggelidou E, et al. An HNF4α-miRNA inflammatory feedback circuit regulates he-patocellular oncogenesis. Cell. 2011; 147(6): 1233-1247. doi: 10.1016/j.cell.2011.10.043
Ning BF, Ding J, Yin C, et al. Hepatocyte nuclear factor 4 alpha suppresses the development of hepatocellular carcinoma. Cancer Res. 2010; 70(19): 7640-7651. doi: 10.1158/0008-5472. CAN-10-0824
Walesky C, Gunewardena S, Terwilliger EF, et al. Hepato-cyte-specific deletion of hepatocyte nuclear factor-4α in adult mice results in increased hepatocyte proliferation. Am J Physiol Gastrointest Liver Physiol. 2013; 304(1): G26-37. doi: 10.1152/ ajpgi.00064.2012
Walesky C, Edwards G, Borude P, et al. Hepatocyte nuclear factor 4 alpha deletion promotes diethylnitrosamine-induced hepatocellular carcinoma in rodents. Hepatology. 2013; 57(6): 2480-2490. doi: 10.1002/hep.26251
Yang M, Li SN, Anjum KM, et al. A double-negative feed-back loop between Wnt-β-catenin signaling and HNF4α regu-lates epithelial-mesenchymal transition in hepatocellular carci-noma. J Cell Sci. 2013; 126(Pt 24): 5692-5703. doi: 10.1242/ jcs.135053
Alder O, Cullum R, Lee S, et al. Hippo Signaling Influ-ences HNF4A and FOXA2 Enhancer Switching during Hepa-tocyte Differentiation. Cell Rep. 2014 Sep 24. pii: S2211-1247- (14):00722-00730. doi: 10.1016/j.celrep.2014.08.046
Saha SK, Parachoniak CA, Ghanta KS, et al. Mutant IDH in-hibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature. 2014; 513(7516): 110-114. doi: 10.1038/ nature13441
Dawson S. Hepatocellular carcinoma and ubiquitin-protea-some system. Biochem. Biophys Acta. 2008; 1782: 775-784. doi: 10.1016/j.bbadis.2008.08.003
Lim IK. Spectrum of molecular changes during hepatocvar-cinogenesis induced by DEN and other chemical in Fishes 344 rats. Mech. Ageing Dev. 2003; 124: 679-708.
Krzywda S, Brzozowski AM, Higashitsuj H, et al. The crys-tal structure of Gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53. J Biol Chem. 2004; 279(2): 1541-1545. doi: 10.1074/jbc.M310265200
Fu HY, Wang HY, Tan L, Liu SQ, Cao HA, Wu MC. Over-expression of p28/Gankyrin in human hepatocellular carcinoma and its clinical significance. World J. Gastroenterol. 2002; 8: 638-643.
Jing H, Zhang G, Meng L, Meng Q, Mo H, Tai Y.Gradually elevated expression of Gankyrin during human hepatocarcino-genesis and its clinicopathological significance. Sci Rep. 2014; 4: 5503. doi: 10.1038/srep05503
Li H, Fu X, Chen Y, et al. Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular car-cinoma. Gastroenterology. 2005; 128: 2029–2041. doi: http:// dx.doi.org/10.1053/j.gastro.2005.03.001
Song X, Wang J, Zheng T, et al. LBH589 Inhibits prolifera-tion and metastasis of hepatocellular carcinoma via inhibition of Gankyrin/STAT3/Akt pathway. Mol Cancer. 2013; 12(1): 114. doi: 10.1186/1476-4598-12-114
Li J, Tian F, Li D, Chen J, Jiang P, Zheng S, Li X, Wang S. MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression. FEBS Lett. 2014; 588(18): 3491-3500. doi: 10.1016/j.febslet.2014.08.008
Jiang Y, Iakova P, Jin J, et al. Farnesoid X receptor inhibits Gankyrin in mouse livers and prevents development of liver can-cer. Hepatology. 2013; 57: 1098-1106. doi: 10.1002/hep.26146
Higashitsuji H, Itoh K, Sakurai T, et al. The oncoprotein Gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell. 2005; 8: 75-87. doi: http:// dx.doi.org/10.1016/j.ccr.2005.06.006
Higashitsuji H, Itoh K, Nagao T, et al. Reduced stability of retinoblastoma protein by Gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nature Medicine. 2000; 6: 96-99.
Li J, Tsai MD. Novel insights into the INK4-CDK4/6-Rb pathway: counter action of Gankyrin against INK4 proteins reg-ulates the CDK4-mediated phosphorylation of Rb. Biochemis-try. 2002; 41: 3977-3983. doi: 10.1021/bi011550s
Sun W, Ding J, Wu K, et al. Gankyrin-mediated dedifferen-tiation facilitates the tumorigenicity of rat hepatocytes and hepa-toma cells. Hepatology. 2011; 54(4): 1259-1572. doi: 10.1002/ hep.24530
Qian YW, Chen Y, Yang W, et al. p28(GANK) prevents degradation of Oct4 and promotes expansion of tumor-initiat-ing cells in hepatocarcinogenesis. Gastroenterology. 2012; 142: 1547-1558. doi: 10.1053/j.gastro.2012.02.042
Zheng T, Hong X, Wang J, et al. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signal-ing in human cholangiocarcinoma. Hepatology. 2014; 59(3): 935-946. doi: 10.1002/hep.26705
Bai Z, Tai Y, Li W, et al. Gankyrin activates IL-8 to pro-mote hepatic metastasis of colorectal cancer. Cancer Res. 2013; 73(14): 4548-4558. doi: 10.1158/0008-5472.CAN-12-4586
Dong LW, Yang GZ, Pan YF, et al. The oncoprotein p28GANK establishes a positive feedback loop in β-catenin signaling. Cell Res. 2011; 21(8): 1248-1261. doi: 10.1038/ cr.2011.103
Fu J, Chen Y, Cao J, et al. p28GANK overexpression ac-celerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1α pathways. Hepatology. 2011; 53(1): 181-192. doi: 10.1002/ hep.24015
Man JH, Liang B, Gu YX, et al. Gankyrin plays an essen-tial role in Ras-induced tumorigenesis through regulation of the RhoA/ROCK pathway in mammalian cells. J Clin Invest. 2010; 120(8): 2829-2841. doi: 10.1172/JCI42542
Mine H, Sakurai T, Kashida H, et al. Association of Gankyrin and stemness factor expression in human colorec-tal cancer. Dig Dis Sci. 2013; 58(8): 2337-2344. doi: 10.1007/ s10620-013-2627-8
Su B, Luo T, Zhu J, et al. Interleukin-1β/IRAK-1 inflam-matory signaling contributes to persistent Gankyrin activation during hepatocarcinogenesis. Hepatology. 2014. doi: 10.1002/ hep.27551
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Cancer Studies and Molecular Medicine (CSMM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
